Canopy Growth Reports Flat Revenue of CA$75 Million; Sarepta Faces Patient Deaths

Canopy Growth reported net revenue of CA$75 million ($54.6 million) for Q3 of fiscal 2026, unchanged from the previous year, with a net loss per share of CA$0.18 ($0.13). Despite a 49% improvement in the bottom line, the company continues to face significant challenges in the cannabis industry, which remains highly regulated and uncertain. Sarepta Therapeutics is dealing with serious complications as its drug Elevidys, for Duchenne muscular dystrophy, has been linked to two patient deaths due to liver failure, leading to a suspension of shipments. These developments indicate prolonged struggles for both companies and potential negative implications for their stock prices.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.